Phase I dose-escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast cancer

Masuda, T; Noda, M; Kogawa, T; Kitagawa, D; Hayashi, N; Jomori, T; Nakanishi, Y; Nakayama, KI; Ohno, S; Mimori, K

Mimori, K (corresponding author), Kyushu Univ, Dept Surg, Beppu Hosp, Beppu, Oita, Japan.

CANCER SCIENCE, 2020; 111 (3): 924